Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
6.4950
+0.0250 (0.39%)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development
By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need.
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares.
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
The AI chipmaker’s $50 million investment in Recursion, unveiled in 2023 to support AI-driven drug discovery, has been a key driver of investor interest.
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market, Exscientia was acquired by another firm last year.
